Chiral Method(手性方法)研究综述
Chiral Method 手性方法 - This study illustrates the usefulness of consistent chromatographic data sets to accelerate and facilitate the identification of chiral methods to separate enantiomers by automated processing and statistical analysis. [1] For the chiral method, an analytical column Lux Cellulose-1® was used. [2] The chemical, physical, and biological properties of DAIs are unknown, despite their being structurally similar to arylidene indanones, primarily due to the lack of racemic or chiral methods. [3] Advantages and limitations of the chiral methods developed by EKC are also discussed. [4] A chiral methodology was developed for the first time to ensure the quality control of ivabradine, a novel anti-ischemic and heart rate lowering drug commercialized as a pure enantiomer. [5] In this study, it was possible to conclude bioequivalence for tmax based on S-ibuprofen, though this conclusion might be questioned if the decision is based on R-ibuprofen or the achiral method. [6] In conclusion, the study demonstrated the value of measuring amphetamine with a chiral method to detect intake of illicit amphetamine and to perform drug testing in oral fluid as a mean for compliance monitoring. [7]这项研究说明了一致的色谱数据集的有用性，以加速和促进手性方法的鉴定，以通过自动处理和统计分析分离对映异构体。 [1] 对于手性方法，使用分析柱 Lux Cellulose-1®。 [2] 尽管 DAI 在结构上与亚芳基茚满酮相似，但其化学、物理和生物学特性尚不清楚，这主要是由于缺乏外消旋或手性方法。 [3] 还讨论了 EKC 开发的手性方法的优点和局限性。 [4] 首次开发了一种手性方法来确保伊伐布雷定的质量控制，伊伐布雷定是一种以纯对映异构体形式商业化的新型抗缺血和降低心率的药物。 [5] 在这项研究中，有可能得出基于 S-布洛芬的 tmax 的生物等效性，尽管如果该决定是基于 R-布洛芬或非手性方法，这一结论可能会受到质疑。 [6] 总之，该研究证明了使用手性方法测量苯丙胺的价值，以检测非法苯丙胺的摄入量，并在口腔液中进行药物测试，作为依从性监测的手段。 [7]
chiral method development 手性方法开发
Due to the complexity and lack of predictability in chiral separations, column screening remains the gold standard to initiate chiral method development for active pharmaceutical ingredients (APIs) and synthetic intermediates. [1] The results of this study bring new information concerning the chiral separation of anionic boron clusters and might be used in the chiral method development process on other chiral selectors. [2] This streamlined OA workflow enables medicinal chemists with limited expertise in chiral method development to successfully and rapidly purify enantiomers for their projects using Waters UPC2 and Prep100-SFC instrumentation. [3]由于手性分离的复杂性和缺乏可预测性，色谱柱筛选仍然是启动活性药物成分 (API) 和合成中间体的手性方法开发的金标准。 [1] 这项研究的结果带来了有关阴离子硼簇手性分离的新信息，并可能用于其他手性选择剂的手性方法开发过程。 [2] 这种简化的 OA 工作流程使在手性方法开发方面专业知识有限的药物化学家能够使用 Waters UPC2 和 Prep100-SFC 仪器为他们的项目成功、快速地纯化对映异构体。 [3]